By 2015, the Brazilian Acute Coronary Syndrome Drug Market Will Nearly Double to $229 Million

Shift to PCI Procedures Will Present Opportunity for Western Brands with Proven Efficacy in PCI Setting, According to a New Report from Decision Resources

BURLINGTON, Mass.--(BUSINESS WIRE)-- Decision Resources, one of the world’s leading research and advisory firms for pharmaceutical and healthcare issues, finds that the acute coronary syndrome (ACS) drug market in Brazil will nearly double from $122 million in 2010 to $229 million in 2015. According to the Emerging Markets report, Acute Coronary Syndrome in Brazil, growth will be driven by the uptake of novel antithrombotic agents as well as an aging Brazilian population, improved access to medical care and a rising number of higher-income patients driving the demand for more expensive drugs. The launch of several novel premium-priced agents will account for approximately 22 percent of total sales in 2015.

Expansion in private health insurance coverage, increases in disposable income among those without health insurance and the expected increase in government healthcare spending will also contribute to a rise in percutaneous coronary intervention (PCI) procedures between 2010 and 2015. This shift presents commercial opportunity for Western brand drugs with proven efficacy in the PCI setting, such as The Medicines Company’s Angiomax/Angiox, Eli Lilly/Daiichi Sankyo’s Effient/Efient and AstraZeneca’s Brilinta/Brilique.

“Although the volume of PCI procedures are rising in Brazil, Brazilian cardiologists tell us that these procedures are still generally reserved for higher-risk ACS patients, while lower-risk patients are treated with medical management. Additionally, the availability of PCI centers varies across regions, so total PCI volume growth in Brazil will be somewhat constrained through 2015,” said Decision Resources Analyst Conor Walsh, Ph.D. “Nevertheless, the growth that does exist will contribute to the associated growth of antithrombotic agents and presents commercial opportunity for manufacturers of these drugs.”

The new report features extensive primary research with Brazilian cardiologists as well as a market outlook by drug and class through 2015 and acute coronary syndrome epidemiology through 2020.

About Emerging Markets Reports

Decision Resources is the first and only company to offer a syndicated report series for high-growth emerging markets with comprehensive disease-specific analysis. Each report assesses the commercial opportunity in the pharmaceutical market for a disease based on population demographics, economic development, disease epidemiology and changing physicians’ practices.

About Decision Resources

Decision Resources ( is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at

All company, brand or product names contained in this document may be trademarks or registered trademarks of their respective holders.


Decision Resources
Lisa Osgood, 781-993-2606
[email protected]
Decision Resources Group
Christopher Comfort, 781-993-2597
[email protected]

KEYWORDS:   United States  North America  Massachusetts

INDUSTRY KEYWORDS:   Health  Biotechnology  Cardiology  Hospitals  Pharmaceutical  Other Health  Professional Services  Insurance  Research  Medical Supplies  Science  General Health